Search
  • Within this site
AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

Fluorescent Amyloid Binding Agents for Diagnosis of Alzheimer's Disease


Technology Benefits

Simple synthesis and chemistries amenable to modification and production at large scales. Fluorescence profile optimized for in vivo characterization of amyloid deposits using existing and widely accessible imaging instruments. These probes may be used for the monitoring of disease progression in the development of new therapeutic treatments.


Technology Application

Fluorescent probes are compatible with in vivo fluorescence imaging instruments. Generally relevant for the early diagnosis of diseases characterized by amyloid aggregates, such as Alzheimer’s, Parkinson, Huntington disease, and rheumatoid arthritis.


Detailed Technology Description

A common structural feature of known amyloid-binding agents is an electronically-polarized, extended aromatic system that is inherent to a family of fluorescent probes known as molecular rotors. Features of molecular rotors, which inherently decrease the non-radiative decay rate and increase fluorescence emission upon binding to aggregated beta-amyloids, were incorporated into a general design of novel, amyloid-binding agents.


Supplementary Information

Patent Number: US20120302603A1
Application Number: US13515239A
Inventor: Yang, Jerry | Theodorakis, Emmanuel A.
Priority Date: 10 Dec 2009
Priority Number: US20120302603A1
Application Date: 9 Aug 2012
Publication Date: 29 Nov 2012
IPC Current: C07C025543 | A61K0031277 | A61K0031451 | A61P002528 | C07D0295155 | G01N002164 | G01N0033566
US Class: 514319 | 436501 | 514521 | 546205 | 558402 | 558403
Assignee Applicant: The Regents of the University of California
Title: AMYLOID BINDING AGENTS
Usefulness: AMYLOID BINDING AGENTS
Summary: For treating a disease caused by accumulation of amyloids in a subject, for treating Alzheimer's disease, bovine spongiform encephalopathy (BSE), Parkinson's disease, Huntington's disease, Down's Syndrome, dementia with Lewy body, or amyotrophic lateral sclerosis (ALS) (all claimed).
Novelty: New 2-cyano-acrylic acid derivatives useful for treatment of e.g. Alzheimer's disease, bovine spongiform encephalopathy, or Parkinson's disease


Industry

Chemical/Material


Sub Group

Chemical/Material Application


Application No.

8940918


Others

State Of Development

Proprietary methods were used to identify, synthesize, and characterize seven, novel compositions of matter. Development included in vitro evaluation for specifications relevant to use in clinical practice, including: solubility, fluorescence characteristics, ability to cross the blood-brain barrier, binding constants, and capability to detect amyloidosis in brain tissue.


Intellectual Property Info

US and numerous foreign rights available for licensure in some fields. US application at link, below.


Related Materials


Additional Technologies by these Inventors


Tech ID/UC Case

20849/2010-162-0


Related Cases

2010-162-0, 2006-105-1, 2006-105-2, 2006-105-4, 2006-105-3, 2007-018-1, 2007-018-2


Country/Region

USA

For more information, please click Here
Business of IP Asia Forum
Desktop View